Verified factor-similar pair

MTUM vs SPMO

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
93
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SPMO has the higher backtested relative Sharpe (1.777 vs 1.403).
  • SPMO has the lower published fee (0.13% vs 0.15%).
  • SPMO is cheaper on dividend valuation (153 vs 182, where 100 is each fund's historical median).
  • MTUM has the stronger regression fit (adjusted R-squared 0.887 vs 0.866).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

MTUM

iShares MSCI USA Momentum Factor ETF
UMD
Adj. R2
0.887
Rel. Sharpe
1.403
Mkt beta
1.08
AUM
US$22.3B
MER
0.15%
Valuation
182

SPMO

Invesco S&P 500 Momentum ETF
UMD
Adj. R2
0.866
Rel. Sharpe
1.777
Mkt beta
1.11
AUM
US$13.4B
MER
0.13%
Valuation
153

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
MTUM
-0.10
|t|
-1.9
SPMO
-0.18
|t|
-2.6
diff +0.08
HML
MTUM
-0.04
|t|
-0.7
SPMO
+0.00
|t|
+0.0
diff -0.04
RMW
MTUM
-0.19
|t|
-3.0
SPMO
-0.18
|t|
-2.4
diff -0.01
CMA
MTUM
+0.10
|t|
+1.3
SPMO
+0.14
|t|
+1.5
diff -0.04
UMD
MTUM
+0.42
|t|
+10.9
SPMO
+0.42
|t|
+8.4
diff +0.01

Why This Pair Matches

Exposure level
94
Exposure shape
99
Mkt beta diff
0.02
Rel. Sharpe diff
0.373

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

MTUM fund page SPMO fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.